Plasma interleukin-6 adds prognostic information in pulmonary arterial hypertension

European Respiratory Journal

Volumn 43, Issue 3, 2014, Pages 912-914

  Heresi, Gustavo A ^a   Aytekin, Metin ^b   Hammel, Jeffrey P ^a   Wang, Sihe ^a   Chatterjee, Soumya ^a   Dweik, Raed A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ERCIYES UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; INTERLEUKIN 6; PROSTACYCLIN;

ADULT; COHORT ANALYSIS; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE TEST; FEMALE; HEART INDEX; HEART RIGHT ATRIUM PRESSURE; HUMAN; LETTER; LUNG PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84895553338     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00164713     Document Type: Letter

References (10)

1. Heresi GA. Clinical perspective: biomarkers in pulmonary arterial hypertension. Int J Clin Pract Suppl 2011; 169: 5-7.
2. Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009; 104: 236-244
3. Genest J. C-reactive protein: risk factor, biomarker and/or therapeutic target? Can J Cardiol 2010; 26: Suppl. A, 41A-44A.
4. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
5. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-870.
6. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
7. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010; 122: 920-927.
8. Selimovic N, Bergh CH, Andersson B, et al. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 2009; 34: 662-668.
9. Rhodes CJ, Wharton J, Howard LS, et al. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart 2011; 97: 1054-1060.
10. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151: 1628-1631.